Article

Australia OKs sales of Norwood epikeratome

Victoria, Australia—Norwood Devices has received Australia's Therapeutic Goods Administration approval to sell its Centurion SES epikeratome. The device won FDA and CE approval in 2004.

Victoria, Australia-Norwood Devices has received Australia's Therapeutic Goods Administration approval to sell its Centurion SES epikeratome. The device won FDA and CE approval in 2004.

Richard Walmsley, chief executive officer of Norwood Devices, said the potential market in Australia is "significant." However, he sees the single-use disposable separator as the "real revenue and profit generator."

The company expects revenues of $14 million Australian ($10.8 million U.S.) in the 2005 calendar year.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.